Ensign Peak Advisors Inc Buys 194,673 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Ensign Peak Advisors Inc raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 108.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 374,673 shares of the company's stock after purchasing an additional 194,673 shares during the period. Ensign Peak Advisors Inc owned about 0.49% of Nurix Therapeutics worth $7,059,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Barclays PLC raised its position in shares of Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after acquiring an additional 56,190 shares in the last quarter. Franklin Resources Inc. increased its position in Nurix Therapeutics by 52.4% in the third quarter. Franklin Resources Inc. now owns 123,101 shares of the company's stock worth $2,766,000 after buying an additional 42,315 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock valued at $1,531,000 after purchasing an additional 31,352 shares during the period. SG Americas Securities LLC increased its holdings in shares of Nurix Therapeutics by 31.1% during the fourth quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock valued at $567,000 after purchasing an additional 7,141 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 21.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock valued at $283,000 after purchasing an additional 2,632 shares during the period.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the transaction, the insider now owns 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at $488,660.76. This trade represents a 14.73% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,838 shares of company stock valued at $221,500. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded up $0.10 during trading hours on Friday, hitting $9.56. The company's stock had a trading volume of 437,181 shares, compared to its average volume of 886,793. The company has a market capitalization of $728.82 million, a PE ratio of -3.31 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56. The stock has a 50 day moving average of $11.07 and a 200 day moving average of $16.91.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same period in the prior year, the firm posted ($0.76) earnings per share. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. decreased their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Needham & Company LLC reiterated a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Wells Fargo & Company decreased their price target on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Finally, Royal Bank of Canada increased their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.